Genetic polymorphism of N-acetyltransferase-2, glutathione S- transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer

Journal of Clinical Pathology

Volumn 51, Issue 4, 1998, Pages 294-298

  Gonzalez M V ^a   Alvarez, V ^a   Pello, M F ^b   Menendez M J ^a   Suarez C ^b   Coto, E ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Servicio de ORL

Author keywords

Cytochrome P450IID6; Cytochrome P450IIE1; Glutathione S transferase; Head and neck squamous cell carcinoma; N acetyltransferase

Indexed keywords

ACYLTRANSFERASE; DEBRISOQUINE 4 HYDROXYLASE; DIMETHYLNITROSAMINE DEMETHYLASE; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ALLELISM; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SQUAMOUS CELL CARCINOMA;

EID: 0031843052     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.51.4.294     Document Type: Article

References (28)

1. Smith CAD, Smith G, Wolf CR. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer 1994;30A:1921-35.
2. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992;339:1375-7.
3. Wolf CR, Smith CAD, Bishop T, et al. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics 1994;4:104-6.
4. Caporaso NG, Hayes RB, Dosmeci M, et al. Lung cancer risk, occupational exposure and the debrosoquine metabolic phenotype. Cancer Res 1989;49:3675-9.
5. Caporaso NG, Tucker MA, Hoover RN, et al. Lung cancer and the debrisoquine metabolic phenotype. J Natl Cancer Inst 1990;82:1262-72.
6. Agúndez JAG, Ledesma MC, Benitez, J, et al. CYP2D6 genes and risk of liver cancer. Lancet 1995;345;830-1.
7. Kato S, Shields PG, Caporaso NE, et al. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 1992;52:6712-15.
8. Hirvonon A, Husgatvel-Pursiainen K, Anttila S, et al. Human CYP2E1 gene and lung cancer. DraI and RsaI restriction fragment length polymorphism in a Finnish study population. Carcinogenesis 1993;14:85-8.
9. Vineis D, Bartsch H, Caporaso N, et al. Genetically based N-acetyltransferase polymorphism and low-level environmental exposure to carcinogens. Nature 1994;369:154-6.
10. Blum M, Demierre A, Grant DM, et al. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 1991;88:5237-41.
11. Hein DW, Doll MA, Rustan TD, et al. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995;55: 3531-6.
12. Hein DW, Ferguson RJ, Doll MA, et al. Molecular genetics of human polymorphic N-acetyltranferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet 1994;3:729-34.
13. Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransterase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995;57:581-92.
14. Risch A, Wallace DMA, Bathers S, et al. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995;4: 231-6.
15. Ilett KF, David KM, Detchon P. Acetylation phenotype in colorectal cancer. Cancer Res 1987;47:1466-9.
16. Ambrosone CB, Freudenheim JL, Graham S, Marshall JR, et al. Cigarette smoking, N-acetyltransferase 2 genetic-polymorphisms, and breast cancer. JAMA 1996;276:1494-501.
17. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988;948:37-66.
18. Hayes JD, Wolf CR. Molecular mechanisms of drug resistance. Biochem J 1990;272:281-95.
19. Drozdz M, Gierek T, Jendryczko A. N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasia 1987;34:481-4.
20. Comstock KE, Sanderson BJS, Claflin G, et al. GSTM1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res 1990;18:3670.
21. Heckbert SR, Weiss NS, Horning SK, et al. Glutathione S-transferase and epoxide hydrolase activity in human leucocytes in relation to risk of lung cancer and other smoking related cancers. J Natl Cancer Inst 1992;84:414-22.
22. Seidegard J, Pero RW, Miller DW, et al. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 1986;7:751-3.
23. Norell SE. Workbook of epidemiology, New York: Oxford University Press, 1995.
24. Cascorbi I, Brockmöller J, Mrozikiewicz PM, et al. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996;56:3961-6.
25. Gonzalez FJ. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar. Cancer Res 1995;55:710-15.
26. González MV, Pello MF, Suárez C, et al. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res 1995;1:1043-9.
27. Gonzȧlez, MV, Pello MF, Suȧrez C, et al. Deletion and methylation of the tumor suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol 1997;50:509-12.
28. Hickman D, Risch A, Buckle V, et al. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J 1994;297:441-5.